Alan M. Fogelman is at the David Geffen School of Medicine at the University of California, Los Angeles, 10833 Le Conte Avenue, Box 951736, Los Angeles, California 90095-1736, USA. He is also a principal in Bruin Pharma, a start up biotech company. afogelman@mednet.ucla.edu
High density lipoprotein (HDL) is often called the 'good cholesterol.' Products of an inflammatory enzyme, myeloperoxidase, are now shown to selectively target the main protein in HDL, apolipoprotein A-I. This turns the 'good cholesterol' bad.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
